Georgios Pampalakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Georgios Pampalakis has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Georgia Sotiropoulou
Department of Pharmacy, School of Health Sciences University of Patras Rion‐Patras Greece
5 shared publications E. Zingkou
Department of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, Greece
1 shared publication- Eleftherios P. Diamandis
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
1 shared publication - Eleni Zingkou
Department of Pharmacy, School of Health Sciences University of Patras Rion‐Patras Greece
1 shared publication - Evangelia Livaniou
Immunopeptide Chemistry Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy and Safety (INRASTES), National Centre for Scientific Research “Demokritos” (NCSRD), Agia Paraskevi 15310, Greece
1 shared publication - Evangelia Prosnikli
Department of Pharmacy, University of Patras, 265 00, Rion-Patras, Greece
1 shared publication
Latest Publications
- 7 January 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (3) , 311-313
Exacerbated dandruff in the absence of kallikrein‐related peptidase 5 protease
- 7 January 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (3) , 311-313
Exacerbated dandruff in the absence of kallikrein‐related peptidase 5 protease
- 1 January 2018
- Published by SAGE Publications in OMICS: A Journal of Integrative Biology
- Vol. 22 (1) , 52-64
Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis
Amyotrophic lateral sclerosis (ALS) is a rare but usually fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and the spinal cord. Two forms are recognized, the familial that accounts for 5–10% and the sporadic that accounts for the rest. New studies suggest that ALS is a highly heterogeneous disease, and this diversity is a major reason for the lack of successful therapeutic treatments. Indeed, only two drugs (riluzole and edaravone) have been approved that provide a limited improvement in the quality of life. Presently, the diagnosis of ALS is based on clinical examination and lag period from the onset of symptoms to the final diagnosis is ∼12 months. Therefore, the discovery of robust molecular biomarkers that can assist in the diagnosis is of major importance. DNA sequencing to identify pathogenic gene variants can be applied in the cases of familial ALS. However, it is not a routinely used diagnostic procedure and most importantly, it cannot be applied in the diagnosis of sporadic ALS. In this expert review, the current approaches in identification of new ALS biomarkers are discussed. The advent of various multi-omics biotechnology platforms, including miRNomics, proteomics, metabolomics, metallomics, volatolomics, and viromics, has assisted in the identification of new biomarkers. The biofluids are the most preferable material for the analysis of potential biomarkers (such as proteins and cell-free miRNAs), since they are easily obtained. In the near future, the biofluid-based biomarkers will be indispensable to classify different ALS subtypes and understand the molecular heterogeneity of the disease.
- 1 January 2018
- Published by SAGE Publications in OMICS: A Journal of Integrative Biology
- Vol. 22 (1) , 52-64
Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis
Amyotrophic lateral sclerosis (ALS) is a rare but usually fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and the spinal cord. Two forms are recognized, the familial that accounts for 5–10% and the sporadic that accounts for the rest. New studies suggest that ALS is a highly heterogeneous disease, and this diversity is a major reason for the lack of successful therapeutic treatments. Indeed, only two drugs (riluzole and edaravone) have been approved that provide a limited improvement in the quality of life. Presently, the diagnosis of ALS is based on clinical examination and lag period from the onset of symptoms to the final diagnosis is ∼12 months. Therefore, the discovery of robust molecular biomarkers that can assist in the diagnosis is of major importance. DNA sequencing to identify pathogenic gene variants can be applied in the cases of familial ALS. However, it is not a routinely used diagnostic procedure and most importantly, it cannot be applied in the diagnosis of sporadic ALS. In this expert review, the current approaches in identification of new ALS biomarkers are discussed. The advent of various multi-omics biotechnology platforms, including miRNomics, proteomics, metabolomics, metallomics, volatolomics, and viromics, has assisted in the identification of new biomarkers. The biofluids are the most preferable material for the analysis of potential biomarkers (such as proteins and cell-free miRNAs), since they are easily obtained. In the near future, the biofluid-based biomarkers will be indispensable to classify different ALS subtypes and understand the molecular heterogeneity of the disease.
- 17 February 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (22) , 3246-3248
“Activography”: a novel, versatile and easily adaptable method for monitoring enzymatic activities in situ
We developed activography to map enzymatic activities on tissue sections using activity-based probes. The assay was validated using a new protease-activity probe on skin biopsies to provide proof-of-concept. Activography is more selective and technically easier than the established in situ zymography, thus, adaptable in routine running clinico-chemical laboratories.
- 17 February 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (22) , 3246-3248
“Activography”: a novel, versatile and easily adaptable method for monitoring enzymatic activities in situ
We developed activography to map enzymatic activities on tissue sections using activity-based probes. The assay was validated using a new protease-activity probe on skin biopsies to provide proof-of-concept. Activography is more selective and technically easier than the established in situ zymography, thus, adaptable in routine running clinico-chemical laboratories.
- 20 March 2016
- Published by Wiley in Chemistry – A European Journal
- Vol. 22 (20) , 6779-6782
The Generation of an Organic Inverted Chemical Garden
A chemical garden based on iron salt that grows in organic solvents and ions is demonstrated for the first time. This prototype chemical garden develops in an inverted orientation, thus providing evidence that downward growth is feasible.
- 20 March 2016
- Published by Wiley in Chemistry – A European Journal
- Vol. 22 (20) , 6779-6782
The Generation of an Organic Inverted Chemical Garden
A chemical garden based on iron salt that grows in organic solvents and ions is demonstrated for the first time. This prototype chemical garden develops in an inverted orientation, thus providing evidence that downward growth is feasible.
- Open Access
- 5 December 2012
- Published by Springer Nature in BMC Chemistry
- Vol. 6 (1) , 148
Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6
- 5 December 2012
- Published by Springer Nature in BMC Chemistry
- Vol. 6 (1) , 148
Open AccessDevelopment and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6
- 1 April 2010
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 391 (4) , 321-31
Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation
Kallikrein-related peptidases (KLKs) constitute a family of 15 highly conserved serine proteases encoded by the largest uninterrupted cluster of protease-encoding genes within the human genome. Recent studies, mostly relying onin vitroproteolysis of recombinant proteins, have suggested that KLK activities are regulated by proteolytic activation cascades that can operate in a tissue-specific manner, such as the semen liquefaction and skin desquamation cascades. The validity of KLK activation cascadesin vivolargely remains to be demonstrated. Here, we focus on recent investigations showing that KLKs represent interesting players in the broader field of immunology based on their ability to bridge their inherent ability to degrade the extracellular matrix with major functions of the immune system. More specifically, KLKs assist in the infiltration of immune cells through the skin and the blood brain barrier, whereas they catalyze the generation of antimicrobial peptides by proteolytic activation and further processing of protein precursors. In an attempt to integrate current knowledge, we propose KLK-mediated pathways that are putatively involved in inflammation associated with skin wounding and central nervous system disorders, including multiple sclerosis. Finally, we present evidence of KLK participation in autoimmune diseases and allergies.
- 1 April 2010
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 391 (4) , 321-31
Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation
Kallikrein-related peptidases (KLKs) constitute a family of 15 highly conserved serine proteases encoded by the largest uninterrupted cluster of protease-encoding genes within the human genome. Recent studies, mostly relying onin vitroproteolysis of recombinant proteins, have suggested that KLK activities are regulated by proteolytic activation cascades that can operate in a tissue-specific manner, such as the semen liquefaction and skin desquamation cascades. The validity of KLK activation cascadesin vivolargely remains to be demonstrated. Here, we focus on recent investigations showing that KLKs represent interesting players in the broader field of immunology based on their ability to bridge their inherent ability to degrade the extracellular matrix with major functions of the immune system. More specifically, KLKs assist in the infiltration of immune cells through the skin and the blood brain barrier, whereas they catalyze the generation of antimicrobial peptides by proteolytic activation and further processing of protein precursors. In an attempt to integrate current knowledge, we propose KLK-mediated pathways that are putatively involved in inflammation associated with skin wounding and central nervous system disorders, including multiple sclerosis. Finally, we present evidence of KLK participation in autoimmune diseases and allergies.
- 1 September 2007
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1776 (1) , 22-31
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer
- 1 September 2007
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1776 (1) , 22-31
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer
- 1 January 2006
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 387 (6) , 795-799
The epigenetic basis for the aberrant expression of kallikreins in human cancers
The tissue kallikrein gene family consists of 15 genes tandemly arranged on human chromosome 19q13.4. Most kallikrein genes are characterized by aberrant expression patterns in various human cancers, a feature that makes them ideal cancer biomarkers. In the present study, we investigated the effect of the epigenetic drug compound 5-aza-2′-deoxycytidine on the expression of downregulated kallikrein genes in prostate, breast, and ovarian cancer cell lines. Reactivation of multiple kallikrein genes was observed, although some of these genes do not contain CpG islands in their genomic sequence. Epigenetic regulation provides a new mechanism for the pharmacological modulation of kallikreins in human cancers with putative therapeutic implications.
- 1 January 2006
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 387 (6) , 795-799
The epigenetic basis for the aberrant expression of kallikreins in human cancers
The tissue kallikrein gene family consists of 15 genes tandemly arranged on human chromosome 19q13.4. Most kallikrein genes are characterized by aberrant expression patterns in various human cancers, a feature that makes them ideal cancer biomarkers. In the present study, we investigated the effect of the epigenetic drug compound 5-aza-2′-deoxycytidine on the expression of downregulated kallikrein genes in prostate, breast, and ovarian cancer cell lines. Reactivation of multiple kallikrein genes was observed, although some of these genes do not contain CpG islands in their genomic sequence. Epigenetic regulation provides a new mechanism for the pharmacological modulation of kallikreins in human cancers with putative therapeutic implications.